Treating Breast Cancer Early with Drugs, Radiation Lowers Odds of Recurrence

According to a new Stanford University study, treating breast cancer early with radiation and drugs significantly lowers the odds of developing a worse form of cancer 15 years down the line. The news, experts hope, will reassure women who are diagnosed with early stages of breast cancer that a more positive prognosis lays ahead.

"We're coming into an era where treatments are going to be more tailored to the individual," said Dr. Irene Wapnir, chief of breast surgery at the Stanford Cancer Center and lead author of the study. "Women who were treated by lumpectomy alone, 65 percent of them didn't have a recurrence of cancer."

This study, which appeared in the Journal of the National Cancer Institute, is the first one that reveals the long-term outlook for women that have been diagnosed with ductal carcinoma in situ (DCIS). DCIS is the most common type of noninvasive breast cancer.

"There is this question around should we even be treating DCIS. We don't know the rate of invasive breast cancer if we do nothing," said Karuna Jaggar, executive director of Breast Cancer Action, a San Francisco advocacy group.

This particular report put together two different clinical trials that were started by the National Surgical Adjuvant Breast and Bowel Project in 1985 and 1991. Data from those particular trials were utilized to compare three separate treatments: lumpectomies, lumpectomies and radiation, and lumpectomies, radiation and five years of using the drug tamoxifen.

The results, which took into account 2,600 women for a time span of five years, noted that breast cancer deaths were the same for all treatment groups. However, women who only had the lumpectomy had a 19 percent recurrence of invasive breast cancer over the next years. On the flip side, only nine percent of women had a lumpectomy and radiation and 8.5 percent of the women who had the lumpectomy, radiation and tamoxifen experienced recurrence of invasive breast cancer.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap